Canopy Growth, Tilray Shares Rise After DOJ Proposes Marijuana Reclassification
By Josh Beckerman
Canopy Growth and Tilray Brands shares rose after the Justice Department submitted a proposed regulation to reschedule marijuana under the Controlled Substances Act.
Shares of Canopy Growth were up 17% to $11.60, while Tilray Brands shares were up 7.5% to $3.01 in recent trading.
The DOJ said the proposal emphasizes marijuana's "currently accepted medical use" in the U.S.
Shares of several cannabis companies increased in late April following an Associated Press report that said the U.S. Drug Enforcement Administration may reclassify marijuana to Schedule III from Schedule I.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
May 16, 2024 14:13 ET (18:13 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening in the Markets This Week
-
4 Top Dividend-Paying REIT Stock Picks
-
After Earnings, Is Netflix Stock a Buy, a Sell, or Fairly Valued?
-
P-CAPE: A Better Way for Investors to Estimate Future Returns
-
Which Stocks Have Driven the Stealth Large-Value Rally?
-
Forecasts for Q2 GDP Report Show a Healthy but Slowing Economy
-
5 Stocks to Buy as the Market Rally Broadens
-
4 Top US Travel Stock Picks
-
How Do Interest Rates Affect Stock Market Returns?
-
American Airlines Earnings: Ticket Distribution Misstep Affected Results
-
Going Into Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
3 Top Cybersecurity Stock Picks for Long-Term Investors
-
AbbVie Earnings: Firm Sees Strong Next-Generation Immunology Drugs Sales
-
Ford Earnings: Warranty Problems on Older Vehicles Slam Results
-
ServiceNow Earnings: Operating on a Higher Plane Within Enterprise Software